Results 91 to 100 of about 86,629 (276)

Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1

Haematologica, 2012
Background Multiple myeloma, a malignancy of the antibody-secreting plasma cells, remains incurable by current therapy. However, the proteasome inhibitor bortezomib and other new drugs are revolutionizing its treatment.
Silvia C. W. Ling, Edwin K. K. Lau, Ammira Al-Shabeeb, Angela Nikolic, Albert Catalano, Harry Iland, Noemi Horvath, P. Joy Ho, Simon Harrison, Shaun Fleming, Douglas E. Joshua, John D. Allen   +11 more
doaj   +1 more source

Cytotoxic drugs activate KSHV lytic cycle in latently infected PEL cells by inducing a moderate ROS increase controlled by HSF1, NRF2 and p62/SQSTM1 [PDF]

, 2018
Previous studies have indicated that cytotoxic treatments may induce or not activate viral lytic cycle activation in cancer cells latently infected by Kaposi’s sarcoma-associated herpesvirus (KSHV). To investigate the molecular mechanisms responsible for
Angiolillo, Camilla, CIRONE, Mara, D’Orazi, Gabriella, FAGGIONI, Alberto, GILARDINI MONTANI, MARIA SAVERIA, GRANATO, Marisa   +5 more
core   +1 more source

Regularized Single‐Cell Imaging Enables Generalizable AI Models for Stain‐Free Cell Viability Screening

Small Methods, EarlyView.
Recent advances in AI suggest the potential for stain‐free cell viability screening on brightfield microscopy images. However, no model has been reliably generalized across previously unseen cell types and compounds. Here, we show that “regularized imaging” of single cells in nanowells enables training of generalizable AI models for stain‐free ...
Pan Deng, Deasung Jang, Samuel G. Berryman, Simon P. Duffy, Hongshen Ma   +4 more
wiley   +1 more source

The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells

Haematologica, 2015
Proteasome inhibitor resistance is a challenge for myeloma therapy. Bortezomib targets the β5 and β1 activity, but not the β2 activity of the proteasome.
Marianne Kraus, Juergen Bader, Paul P. Geurink, Emily S. Weyburne, Anne C. Mirabella, Tobias Silzle, Tamer B. Shabaneh, Wouter A. van der Linden, Gerjan de Bruin, Sarah R. Haile, Eva van Rooden, Christina Appenzeller, Nan Li, Alexei F. Kisselev, Herman Overkleeft, Christoph Driessen   +15 more
doaj   +1 more source

Combination of low-dose rituximab, bortezomib and dexamethasone for the treatment of autoimmune hemolytic anemia

, 2022
Mingkang Yao, Jingjing Zhang, Ying Li, Linlin Lv, Lu Jia, Chunyan Yang, Yu Huang, Haihui Liu, Jian Wang, Mingtai Chen, Hao Zhang   +10 more
openalex   +1 more source

TrkA abundance is increased in cutaneous nerves in bortezomib‐induced neuropathy

Brain Pathology, EarlyView.
Cutaneous nerves in bortezomib‐induced peripheral neuropathy (BIPN) show reduced nerve fiber density, increased TrkA expression, and enhanced dermal angiogenesis, highlighting a pathological switch in NGF/TrkA signaling that may contribute to nerve damage and pain. Abstract Tropomyosin receptor kinase A (TrkA), a high‐affinity receptor for nerve growth
Yuying Jin, Nadine Cebulla, Daniel Schirmer, Eva Runau, Leon Flamm, Calvin Terhorst, Laura Jähnel, Johanna Güse, Nicola Giordani, Annett Wieser, Julian Brennecke, Annemarie Sodmann, Martin Kortüm, Robert Blum, Claudia Sommer   +14 more
wiley   +1 more source

Bortezomib Prescription Pattern for the Treatment of Multiple Myeloma by Hematologists in Nigeria

Journal of Global Oncology, 2017
Purpose: Novel therapy has dramatically changed the outcome of patients with myeloma. Current National Comprehensive Cancer Network guidelines give bortezomib-based combinations a central role in the management of multiple myeloma (MM).
Kaladada I. Korubo, Anazoeze J. Madu, Helen C. Okoye, Benedict Nwogoh   +3 more
doaj   +1 more source

Radiosensitization of noradrenaline transporter-expressing tumour cells by proteasome inhibitors and the role of reactive oxygen species [PDF]

, 2013
Background The radiopharmaceutical 131I-metaiodobenzylguanidine (131I-MIBG) is used for the targeted radiotherapy of noradrenaline transporter (NAT)-expressing neuroblastoma.
Babich, J.W., Boyd, M., Mairs, R.J., Rae, C., Tesson, M.   +4 more
core   +3 more sources

PSMD12 Overexpression Promotes Lung Adenocarcinoma Progression via Ubiquitin–Proteasome Pathway Dysregulation

Cancer Science, EarlyView.
PSMD12, located on the frequently amplified 17q region in LUAD, is upregulated in tumors and associated with poor prognosis and advanced stage. Functional studies revealed that PSMD12 promotes cell proliferation and G2/M transition by inhibiting CDK1 ubiquitination and stabilizing CDK1.
Yuya Ono, Hajime Otsu, Takaaki Masuda, Keisuke Kosai, Shohei Shibuta, Kosuke Hirose, Takashi Ofuchi, Yuki Ando, Koto Kawata, Yasuo Tsuda, Yusuke Yonemura, Taro Tobo, Tomoyoshi Takenaka, Tomoharu Yoshizumi, Koshi Mimori   +14 more
wiley   +1 more source

Comparative Effectiveness and Safety of PI‐Rd Triplets in Relapsed/Refractory Multiple Myeloma: INSIGHT‐MM Data Analysis

European Journal of Haematology, EarlyView.
Assessment of the comparative effectiveness and safety of three PI‐Rd triplets in relapsed/refractory multiple myeloma using data from the global, non‐interventional, observational INSIGHT‐MM study. ABSTRACT Objectives To assess the effectiveness/safety of three proteasome inhibitors (PIs), plus lenalidomide‐dexamethasone (Rd) triplet regimens, for the
Noemi Puig, Xavier Leleu, Hans C. Lee, Faith E. Davies, Roman Hájek, Vania Hungria, Michael A. Thompson, Gordon Cook, Jorge Vela Ojeda, Katja C. Weisel, Jesus G. Berdeja, Saad Z. Usmani, Argiris Symeonidis, Isabel Nascimento‐Ferreira, David Arthur, Lenka Mokrá, Kaili Ren, Dasha Cherepanov, Evangelos Terpos   +18 more
wiley   +1 more source